The center will support development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures, ensure domestic pandemic influenza vaccine manufacturing surge capacity, share facility construction costs, and provide workforce development training programs to address the US government’s preparedness priorities and needs.
Emergent BioSolutions president Daniel J. Abdun-Nabi said,”We are honored by the U.S. government’s continued confidence in us, which is founded on our longstanding track record of being the premier biodefense developer and supplier of medical countermeasures.”
The contract valued at approximately $220m (Cost-shared between the Government and Emergent) includes an 8-year base period of performance and up to 17 additional 1-year option periods.
The agreement was granted through HHS Solicitation No. 11-100-SOL-00011, funded by the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services.